Search Within

Sarat Chandarlapaty

  1. "Steven Sugarman"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  2. Breast Medicine Service (8)
  3. Department of Medicine (8)
  4. GSK Faculty (8)
  5. Human Oncology and Pathogenesis Program (8)
  6. Solid Tumor Oncology Division (8)

More Groups

People
  1. Clifford Hudis (8)
  2. Steven Sugarman (8)
  3. Sujata Patil (7)
  4. Larry Norton (6)
  5. Shanu Modi (6)
  6. Gabriella D'Andrea-Carlino (5)

More People

Years
  1. 2016 (1)
  2. 2015 (3)
  3. 2014 (1)
  4. 2011 (2)
  5. 2008 (1)
Publications
  1. Cancer Research (3)
  2. Annals of Oncology (1)
  3. Breast Cancer Research and Treatment (1)
  4. Clinical Breast Cancer (1)
  5. Clinical Cancer Research (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (1)
  3. Elsevier Inc. (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save